NRX Pharmaceuticals Inc (NRXP) - Total Assets
Based on the latest financial reports, NRX Pharmaceuticals Inc (NRXP) holds total assets worth $15.00 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NRX Pharmaceuticals Inc balance sheet quality to measure how much of total assets are equity-financed.
NRX Pharmaceuticals Inc - Total Assets Trend (2017–2024)
This chart illustrates how NRX Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Check NRXP cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
NRX Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
NRX Pharmaceuticals Inc's total assets of $15.00 Million consist of 90.4% current assets and 9.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 39.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how NRX Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NRXP market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NRX Pharmaceuticals Inc's current assets represent 90.4% of total assets in 2024, an increase from 0.8% in 2017.
- Cash Position: Cash and equivalents constituted 39.5% of total assets in 2024, up from 0.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
NRX Pharmaceuticals Inc Competitors by Total Assets
Key competitors of NRX Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
NRX Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.29 | 0.20 | 0.14 |
| Quick Ratio | 0.29 | 0.20 | 0.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-28.65 Million | $-16.19 Million | $-527.05K |
NRX Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between NRX Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.90 |
| Latest Market Cap to Assets Ratio | 16.14 |
| Asset Growth Rate (YoY) | -50.1% |
| Total Assets | $3.65 Million |
| Market Capitalization | $58.91 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values NRX Pharmaceuticals Inc's assets at a significant premium (16.14x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: NRX Pharmaceuticals Inc's assets decreased by 50.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NRX Pharmaceuticals Inc (2017–2024)
The table below shows the annual total assets of NRX Pharmaceuticals Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.65 Million | -50.09% |
| 2023-12-31 | $7.32 Million | -71.66% |
| 2022-12-31 | $25.82 Million | -21.12% |
| 2021-12-31 | $32.73 Million | +1012.85% |
| 2020-12-31 | $2.94 Million | -90.83% |
| 2019-12-31 | $32.07 Million | -54.69% |
| 2018-12-31 | $70.80 Million | +1.77% |
| 2017-12-31 | $69.57 Million | -- |
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in p… Read more